Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Meiji Starts Japan PIII Trial of Rezurock for CLAD
Meiji Seika Pharma said on March 5 that it has launched a domestic PIII clinical trial of its selective ROCK2 inhibitor Rezurock (belumosudil) in adults with chronic lung allograft dysfunction (CLAD), aiming to expand the drug’s indications in Japan. The…
To read the full story
BUSINESS
- Sephience Seen as Potential First-Line PKU Therapy: Professor
March 27, 2026
- Takeda to Nominate CEO-Elect Kim to Board at June AGM
March 27, 2026
- Meiji Pharma, KM Biologics Begin PIII for 6-in-1 Vaccine
March 27, 2026
- J-TEC Files Dried Allogeneic Cultured Epidermis in Japan
March 27, 2026
- Pfizer Seeks Methotrexate Label Expansion for GVHD Prevention
March 27, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…